The scope of clinical and laboratory manifestations of the antiphospholipid syndrome (APS)
has increased dramatically since its discovery in 1983, where any organ system can be …

Background Autoantibodies to apolipoprotein A‐1 (anti‐ApoA‐1 IgG) were shown to predict
major adverse cardiovascular events and promote atherogenesis. However, their potential …

Abstract Background and aims Antiphospholipid Syndrome (APS) is often complicated by
ischemic vascular events. Vitamin K Antagonists (VKAs) reduce the risk of recurrent …

Antiphospholipid syndrome (APS) affects young patients in the most productive years of their
life, and the consequences of organic or tissue damage involve a decrease in health-related …

Subacute-acute, hyperacute, or even catastrophic and fulminant respiratory events occur in
almost all classic connective tissue disorders (CTDs); they may share systemic life …

The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4% to 5.5%, but its
predictors are poorly known. It was the study objective to evaluate the impact of baseline …

Our previous study demonstrated that Toll-like receptor 4 (TLR4) plays a vital role in the
maturation of bone marrow-derived dendritic cells (BMDCs) from the mice immunized with …

Antiphospholipid syndrome is an autoimmune disorder characterized by vascular
thromboses and pregnancy morbidity associated with antiphospholipid antibodies: lupus …

El término síndrome antifosfolipídico (SAF)“catastrófico” fue introducido para definir una
forma grave y rápidamente evolutiva de SAF que conduce a insuficiencia multiorgánica. Los …